Welcome to the Canadian Entrepreneurs in Life Science – San Francisco Chapter (CELS-SFO) COHORT Program event. In cooperation with the Consulate General of Canada, CELS-SFO, supports Canadian Life Science entrepreneurs through networking, mentorship, and exposure to the local investment community.
In particular, the CELS-SFO COHORT Program taps into the wealth of experienced talent in the Bay Area to help selected Canadian Life Science Startups achieve their specific objectives on the path to commercialization.
This event will provide details on the CELS-SFO COHORT Program including the roles and expectations of the CELS-SFO Mentors and COHORT Program Companies.
Thank you for taking the time out of your busy schedules to help support Canadian Life Science innovators meet their fullest potential.
Follow us on LinkedIn and Twitter and for more information, please visit www.cels-sfo.com
Catherine Love | Director, Capital Services, MaRS Discovery District read bio»
Parimal Nathwani | Vice President of Commercialization, MaRS Innovation read bio»
2:00 PM | Registration and Networking
2:25 PM | Opening Remarks
2:30 PM | CELS-SFO COHORT Program Introduction and Overview
3:00 PM | Featured Canadian Start-up Company Presentations
3:30PM | Networking
4:00 PM | Program Close
Have questions about CELS COHORT Mentor Program – Launch Event? Contact CELS - SFO
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Catherine Love | Director, Capital Services, MaRS Discovery District
Catherine Love has over 15 years of experience in life science investing including public and private equities. As Director, Capital Services at MaRS, she focuses on advising life science and other technology ventures looking to raise Series A to later rounds of capital and bringing international investors to MaRS. Before joining MaRS, Catherine held positions including sell-side biotechnology equity analyst with Mackie Research, Director of Life Sciences venture capital with BDC Venture Capital, and corporate investor relations roles with MDS Inc. and Medicago. Catherine received her BSc in Biochemistry from McGill University, MSc in Organic Chemistry from the University of Toronto and holds the Chartered Financial Analyst designation.
^ Back to speakers' list ^
Parimal Nathwani | Vice President of Commercialization, MaRS Innovation
Parimal Nathwani has over 15 years of experience in various aspects of the biotechnology industry, including corporate finance, business development, transactions, intellectual property management, technology development and operations. He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital, and in- and out-licensing activities. Before joining MaRS Innovation, Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly-traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women's and Children's Hospital as part of his role at the University of British Columbia's Industry Liaison Office, and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters. Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia. He currently sits on the board of ScarX Therapeutics (Chairman), Zucara Therapeutics, and is an observer on the boards of Encycle Therapeutics and Vasomune Therapeutics.